RxDoctor Payments Data

Stefanie Morris

Family · Germantown, TNNPI 1437646510

Payments from drug & device makers

$9,682in general payments, 2019–2025

Across 523 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$759
  • Madrigal Pharmaceuticals$466
  • Johnson & Johnson$392
  • Sanofi$373
  • plus $4K from 25 others

What the payments were for

  • Speaking & faculty fees$1502%
  • Food & beverage$9,39497%
  • Education$1391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,682 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$111,483
Medicare patients
787
Services billed
1,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide118$110,346
CreonLipase/Protease/Amylase33$76,065
Mesalamine59$29,857
ClenpiqSod Picosulf/Mag Ox/Citric Ac131$20,832
Pantoprazole Sodium518$9,627
Budesonide DrBudesonide37$5,219
Mesalamine ErMesalamine24$5,140
Dexlansoprazole DrDexlansoprazole18$5,092
Ursodiol28$4,769
Colesevelam Hcl35$3,854
Balsalazide Disodium11$3,239
Lactulose91$2,888
Misoprostol19$2,421
Dicyclomine Hcl167$2,407
Esomeprazole Magnesium89$2,351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$2,292$186,411151 claims
Ferring Pharmaceuticals Inc.Clenpiq$53$20,832131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →